• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
BIF
Click for more information
2.00% $1.53

Booster Innovation Fund Units - Charts / Financials

watchlist Created with Sketch. Add to my watchlist
refresh Created with Sketch. REFRESH
Day
Open $1.53   Day High $1.53   Day Low $1.53
Daily Volume 61
Bids   Sellers
Number Price Volume   Number Price Volume
0 $1.50 2072   0 $1.53 3888

Data source: Refinitiv

(20min delay)
Last
$1.53 		Change
0.030(2.00%) 		Mkt cap ! n/a
Open High Low Value Volume
$1.53 $1.53 $1.53 $93 61

Buyers (Bids)

No. Vol. Price($)
0 2072 $1.50
 

Sellers (Offers)

Price($) Vol. No.
$1.53 3888 0
Last trade - 03.59am 02/10/2024 (20 minute delay) ?

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Failure to report prompts ASX to impose multiple company suspensions The ASX today told more than 20 companies across many sectors that it would be imposing suspensions on them
Iress runs 'hot' for Wealth Within's stock tips Financial services software play Iress (ASX:IRE) is the HotCopper Hot Stock tip this week from Wealth Within's chief analyst Dale Gillham and senior analyst Fil Tortevski.
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.